Logo-ddj
Submitted: 01 Jun 2022
Revision: 03 Sep 2022
Accepted: 04 Sep 2022
ePublished: 01 Dec 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Dis Diagn. 2023;12(1): 47-51.
doi: 10.34172/ddj.2023.425
  Abstract View: 196
  PDF Download: 173

Review Article

Feasibility of Utilizing Transforming Growth Factor Beta as a Biomarker of Depression in Hospitalized Patients

Seyed Alireza Seyed Ebrahimi 1 ORCID logo, Zahra Sadat Goli 2*, Leila Sadat Mirseify 3, Mohammad Reza Seirafi 2

1 Department of General Psychology, Faculty of Humanities, Islamic Azad University, Isfahan, Badrud, Iran.
2 Islamic Azad University, Kish Branch, Iran.
3 Department of Psychology, Azad University, Kashan Branch, Isfahan, Iran.
*Corresponding Author: Correspondence to Zahra Sadat Goli, Email: , Email: prof.academicmed@gmail.com

Abstract

Several mental conditions and depression, have been linked to immune response disorganization. However, it is unclear if particular immune mediators play a part in the etiopathogenesis of depression. Although there are no definite biomarkers to diagnose depression, the current study sought to logically evaluate the possibility and feasibility of checking a biomarker for depression to be utilized for hospitalized patients suspected of depression. In this narrative review, related articles were gathered through a search of PubMed, Scopus, and ScienceDirect databases as well as a manual search of full-text paper references. The reviewed studies demonstrated the potential role of the transforming growth factor beta (TGF-β) in depressive disorders. Previous studies represented a negative role for TGF-β in depression pathophysiology and an increase in TGF-β after depression treatment. Elevated plasma TGF-alpha acted controversial to TGF-β. The level of TGF-β in maternal plasma increased getting close to delivery, and researchers found that it might be associated with postpartum depression. In addition, researchers reported extreme elevations in TGF-β levels in the brain cells of subjects who died by suicide. Although the results of this study revealed a plausible link between TGF-β and depression based on the literature, sensitivity and specificity studies needed before TGF-β as a biomarker may be extensively employed in clinical practice. Depression appears to be down-regulating TGF-β and its signaling or the underlying mechanisms of the pathogenesis of consequent neurological disorders, while further studies are required for the application of the TGF-β assessment in clinical practice.
First Name
Last Name
Email Address
Comments
Security code


Abstract View: 197

Your browser does not support the canvas element.


PDF Download: 173

Your browser does not support the canvas element.